# Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

> **NCT01958918** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 712 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT01958918
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-23
- **Primary completion:** 2016-11-22
- **Final completion:** 2017-05-29
- **Target enrollment:** 712 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958918, "Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01958918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*